New cancer drug TORL-1-23 enters first human tests
NCT ID NCT05103683
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find the right dose, and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TORL-1-23 (an antibody drug conjugate)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial with only 90 participants, so it is too soon to know if it works. Side effects are unknown, and the drug may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact
Contact
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Providence Medical Foundation
RECRUITINGFullerton, California, 92835, United States
Contact
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact
Contact
-
Sarah Cannon Research Institute Texas Oncology
RECRUITINGTyler, Texas, 75702, United States
Contact
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact
Contact
-
Severance Hospital
RECRUITINGSeoul, 03723, South Korea
Contact
Contact
-
St. Vincent's Hospital, The Catholic University of Korea
RECRUITINGSuwon, Gyeonggi-do, 16247, South Korea
Contact
Contact
-
UCLA - JCCC Clinical Research Unit
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-••••
-
University of Kentucky Medical Center
RECRUITINGLexington, Kentucky, 40536, United States
Contact
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-••••
Contact
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact